MHRA
- Local brand name: Kyprolis
- Status: approved
🇬🇧 Kyprolis in United Kingdom
NICE has issued 4 UK HTA decisions
Marketing authorisation
Health technology assessment
4 decisions from NICE for Kyprolis in United Kingdom.
NICE TA841 — — Appraisal terminated
- Indication assessed: treating relapsed or refractory multiple myeloma (terminated appraisal)
NICE made a decision to terminate the appraisal of Kyprolis for treating relapsed or refractory multiple myeloma. This decision means that NICE will not make a recommendation on the use of Kyprolis for this indication. The decision to terminate was made without a recommendation on the cost-effectiveness of Kyprolis, as no cost-effectiveness analysis was reported.
NICE TA727 — — Appraisal terminated
- Indication assessed: treating relapsed or refractory multiple myeloma (terminated appraisal)
NICE made a decision to terminate the appraisal of Kyprolis for treating relapsed or refractory multiple myeloma. This decision means that the appraisal process for this indication has been stopped. The decision was made without a recommendation on the cost-effectiveness of Kyprolis, as the appraisal was terminated.
NICE TA695 — ✓ Recommended
- Indication assessed: previously treated multiple myeloma
NICE recommended Kyprolis for the treatment of previously treated multiple myeloma. This decision was made based on a patient access scheme and commercial arrangement. No restrictions were placed on the use of Kyprolis.
NICE TA657 — ✓ Recommended
- Indication assessed: previously treated multiple myeloma
NICE recommended Kyprolis for the treatment of previously treated multiple myeloma. This decision was made based on a commercial arrangement and a Patient Access Scheme. No restrictions were placed on the use of Kyprolis.
Kyprolis in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United Kingdom
Frequently asked questions
Is Kyprolis approved in United Kingdom?
Yes. MHRA has authorised it.
Who is the marketing authorisation holder for Kyprolis in United Kingdom?
Amgen is the originator. The local marketing authorisation holder may differ — check the official source linked above.
Has Kyprolis been assessed by UK health technology agencies?
Yes — 4 UK HTA decisions on record from NICE.